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OBJECTIVE: To compare the frequency and immunohistochemical profiles of triple-negative breast carcinomas in
younger and older women.
METHODS AND RESULTS: We selected patients diagnosed with triple-negative breast carcinomas. The groups
examined were women who were 35 years old or younger between 1997 and 2007 (n = 74) and, for comparison,
women who were 60 years old or older (n = 19, consecutive cases). All formalin-fixed and paraffin-embedded tumor
samples were reviewed and immunohistochemically stained for ER, PR, HER2, Ki-67 antigen, epidermal growth
factor receptor, cytokeratin 5/6, p53, vimentin, CD117, and p63 using tissue microarrays blocks. Triple-negative
breast carcinomas corresponded to 34.6% (74/213) of the carcinomas from the younger patients and 16.2% (19/117)
of the carcinomas from the older patients (p = 0.002). No significant differences in the frequency of the basal
phenotype were observed in the two patient groups based on CK5/6 and/or epidermal growth factor receptor
expression (74.3% vs. 68.4%). However, triple-negative breast carcinomas in the older patients presented a higher
frequency of CK5/6 expression compared to those of younger patients (42.1% vs. 9.6%; p = 0.005), whereas triple-
negative breast carcinomas of younger patients had a higher expression level of epidermal growth factor receptor
(71.6% vs. 47.3%).
CONCLUSIONS: These results show that there were significant molecular differences between the triple-negative
basal-like breast carcinomas that were diagnosed in younger women and those that were diagnosed in older
women. These findings may provide a basis for describing the more aggressive phenotype of the triple-negative
breast carcinomas observed in younger women.
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INTRODUCTION
Breast cancer detected in younger patients has been
associated with a more aggressive phenotype.1-3 To improve
treatment outcomes and to reduce mortality from this
disease, a greater understanding of this aggressive pheno-
type is needed. Gene-expression profiling using DNA
microarrays has identified five subtypes of breast cancer
(i.e., luminal A, luminal B, normal breast-like, HER2-over-
expression, and basal-like). Each of these subtypes is
associated with a distinct prognosis, but the different sub-
types share similarities. For example, immunohistochemistry
has been used to evaluate the expression of estrogen recep-
tors (ERs), progesterone receptors (PRs), HER2, and Ki-67 to
characterize the different subtypes.4 The basal-like and
HER2+ subtypes both have a shorter relapse-free survival
and overall survival than luminal tumors.5,6 Triple-negative
(TN) breast carcinomas (i.e., ER-negative, PR-negative, and
HER2-negative tumors) have been shown to be related to a
basal-like phenotype and, accordingly, exhibit more aggres-
sive clinical and pathologic features.7 Triple-negative carci-
nomas are also more prevalent among specific subgroups of
women, particularly younger patients, and have been found
to be associated with BRCA1 germline mutations.8-11
Although significant overlap in criteria of classification of
TN, basal-like carcinomas, and BRCA1-related tumors has
been shown, these three tumor types are not synonymous.
Therefore, no consensus exists regarding the criteria that
identify basal-like subgroups of TN carcinomas. Currently,
the most useful criteria have been the expression of basal-
cytokeratin (CK5/6) and/or epidermal growth factor recep-
tor (EGFR);12 however, recent studies have indicated that TN
carcinomas are not as homogeneous as they were first
thought to be.7,13,14 In this study, the frequencies and
Copyright  2010 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
CLINICS 2010;65(10):1033-1036 DOI:10.1590/S1807-59322010001000019
1033
phenotypic characteristics of TN and basal-like carcinomas in
patients who were 35 years old or younger were analyzed
and compared with those of TN carcinomas diagnosed in
patients who were 60 years old and older.
METHODS AND MATERIALS
This project was approved by the Scientific Committee of
the Department of Pathology of the Faculdade de Medicina
da Universidade de Sao Paulo and by the Ethical Committee
for Research Projects of the Hospital das Clinicas da
Faculdade de Medicina da Universidade de Sao Paulo
(CAPPesq) (protocol 563/07). Between 1997 and 2007, 213
tumor specimens from patients who were 35 years old or
younger were registered at the Consultoria em Patologia, a
large reference laboratory located in Botucatu, Sao Paulo,
Brazil. An additional 117 tumor samples from patients who
were 60 years old or older were also analyzed by the same
laboratory in 2006. All tumor samples from the two age
groups were reviewed and classified according to histolo-
gical type, histological grade, nuclear grade, the presence of
tumor necrosis, the presence of an in situ component, and
any vascular involvement.
For each tumor, representative areas were selected to
construct tissue microarrays (TMAs). Briefly, three cylin-
ders, each 1.5 mm in diameter, were removed from selected
areas of donor blocks and mounted into paraffin blocks at
1-mm intervals using a precision microarray instrument
(Beecher Instruments, Silver Spring, MD). A grid system
was established, and each core had a coordinate reference
(i.e., x-axis, y-axis) for sample identification. Blocks were
sealed at 60 C˚ for 10 min, and 5-mm sections of the resulting
TMA blocks were prepared using standard techniques and
mounted on StarfrostH slides.
Histological sections from the TMA blocks were immu-
nostained for ER, PR, HER2, Ki-67 antigen, EGFR, CK5/6,
p53, vimentin, CD117, and p63. The sources and dilutions of
the antibodies and the epitope retrieval methods that were
used are listed in Table 1. Bound antibodies were detected
using Novolink system (Leica, USA).
Positive immunohistochemistry staining was used to
identify cytoplasmic localization of CK5/6, vimentin, and
CD117; nuclear localization of ER, PR, Ki-67, p63, and p53;
and membranous-pattern staining of EGFR and HER2. In this
study, only cases that had no ER- or PR-positive cells, were
negative for HER2, and were scored as 0 or 1+ according to
the guidelines of the American Society of Clinical Oncology
(ASCO) and College of American Pathologists (CAP)15 were
included. Ki-67 expression was scored as either , 25% or .
25%. For the other markers, at least 1% of the positive cells
with a moderate to strong intensity were considered positive.
Statistical analysis was performed using a two-way
contingency table and the chi-square test.
RESULTS
Triple-negative breast carcinomas were diagnosed in 74/
213 (34.7%) patients who were 35 years old or younger and
in 19/117 (16.2%) patients who were 60 years old or older (p
= 0.002). The median ages of the younger and older patients
who were included in the study were 32 years (mean¡ SD:
30.9 ¡ 3.94; range: 21-35 years) and 73 years (mean ¡ SD:
73.7¡ 7.53; range: 61-91 years), respectively. In the younger
group, 67/74 (90.5%) tumors were of a ductal histological
type; other histological types identified included metaplas-
tic (2 cases), pleomorphic lobular (2 cases), secretory (1
case), mucinous (1 case), and medullary (1 case). Regarding
the older patients, 15/19 (78.9%) tumors were of a ductal
histological type, and 4 (21.1%) were of a pleomorphic
lobular type. The pathological features of the tumors that
were identified in each patient group are summarized in
Table 2. The histological and nuclear grades and the
angiovascular involvement were not different between the
two patient groups. Tumoral necrosis was more frequently
observed in tumors that were derived from younger
patients than in those from older patients (52.7% vs.
31.6%, respectively). However, the difference was not
statistically significant. The basal phenotype, which was
determined by the expression of EGFR and/or CK5/6
according to the criteria of Nielsen et al.,12 was similar for
both groups (74.3% for younger patients vs. 68.4% for older
patients). However, the two markers showed differences in
Table 1 - Reagents and methods used for
immunohistochemical analysis.
Antigen Clone/Source Dilution
Epitope retrieval
method
ER R; SP1/Thermo
Scientific
1 : 500 Pressure cooker, 9 min
PR M; PgR636/Dako 1 : 1000 Pressure cooker, 9 min
HER2 R; SP3/Thermo
Scientific
1 : 100 Microwave oven
p53 protein M; DO-7/Dako 1 : 2700 Pressure cooker, 8 min
Ki-67 M; MIB1/Dako 1 : 600 Pressure cooker, 8 min
EGFR M; 31G7/Zymed 1 : 200 0.1% Pronase, RT, 15 min
p63 protein M; 4A4/Dako 1 : 300 Pressure cooker, 8 min
Vimentin M; V9/Dako 1 : 200 Microwave oven
c-kit (CD117) R; polyclonal/Dako 1 : 50 Microwave oven
CK5/6 M; D5/16B4/Dako 1 : 100 Microwave oven
ER: Estrogen receptor; PR: Progesterone receptor; EGFR: Epidermal
growth factor receptor; CK: cytokeratin
Pressure cooker: citrate buffer (pH 6) (Tender Cooker, Nordic Wave, USA)
Microwave: citrate buffer (pH 6), 15 min (Eletrolux, 900 W)
Table 2 - Pathological and immunohistochemical features
of TN Breast carcinomas in younger (# 35 years) vs. older
($ 60 years) patients.
Variable
# 35 years
(n = 213)
N (%)
$ 60 years
(n = 117)
N (%) p-value1
TN carcinomas 74 (34.7) 19 (16.2) 0.0004
Histological grade 3 56 (75.7) 14 (73.7) NS2
Nuclear grade 3 55 (74.3) 14 (73.7) NS
LVI3 12 (16.2) 2 (10.5) NS
Tumoral necrosis 39 (52.7) 6 (31.6) NS
Basal-like molecular profile4 55 (74.3) 13 (68.4) NS
CK5/6 7 (9.4) 8 (42.1) 0.0005
EGFR 53 (71.6) 9 (47.3) 0.0045
Ki-67 (.25%) 51 (68.9) 12 (63.1) NS
p63 1 (1.3) 0 NS
p53 26 (35.1) 7 (36.8) NS
Vimentin 31/71 (43.7)5 5/18 (27.8)5 NS
c-kit 15/71 (21.2)5 7 (36.8) NS
1Pearson’s chi-square test
2Non-significant
3Lymphovascular invasion
4EGFR and/or CK5/6 positive
5Two cases in the younger group and one case in the older group could
not be assessed
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the frequency between the two groups (Figures 1 and 2).
Tumors that were derived from the younger patients were
more frequently EGFR positive (71.6% vs. 47.3%, respec-
tively) and exhibited a lower frequency of CK5/6 expression
(9.4% vs. 42.1%, respectively). Regarding the basal-like
tumors of younger patients, 53/55 (96.4%) were associated
with EGFR expression, whereas in the older patient group, 9/
13 (69.2%) expressed EGFR (p = 0.0018). c-KIT expression
was also observed more frequently in tumors that occurred in
older patients (36.8%) than in younger patients (21.2%),
although the difference was not significant. The analysis of
other markers, including Ki-67, p63, p53, and vimentin, did
not show any significant differences between the two groups.
DISCUSSION
Breast cancer that is detected in younger women is
typically associated with aggressive behavior and results in
a poor prognosis. Unfortunately, the specific mechanisms
responsible for this tumor phenotype remain unclear. This
poor understanding is further complicated by the controver-
sial results of many studies. Currently, breast cancers that are
diagnosed in younger patients are characterized by reduced
hormone sensitivity and high HER2/EGFR expression,2,16
although ER-positive carcinomas are still a prevalent
subgroup of tumors in this age group.1,16 Furthermore,
luminal carcinomas in younger women are mostly subtype B,
which is determined by their frequent co-expression of HER2
and/or their high proliferative activity.16 Triple-negative
carcinomas tend to occur less frequently than luminal car-
cinomas; however, triple-negative carcinomas are more
prevalent in patients who are younger than 35 years old.17
TN carcinomas are considered to be a group of biolo-
gically distinct neoplasias that mostly exhibit a basal
phenotype and an aggressive biology. Unlike the other
subtypes, targeted agents that are specifically aimed at
triple-negative breast tumors are not yet available; thus, this
deficiency intensifies the need and interest in advancing
novel therapeutic strategies beyond chemotherapy for this
subset of high-risk patients. Triple-negative is a term based
on clinical assays for ER, PR, and HER2, whereas basal-like
is a molecular phenotype that was initially defined using
cDNA microarrays. However, low-grade tumors, such as
adenoid cystic and medullary carcinomas, are also con-
sidered TN carcinomas.13,18 Therefore, the best criteria to
characterize the phenotype of basal carcinomas have
remained somewhat controversial. Nielsen et al. proposed
that the best immunohistochemistry predictors of basal-like
gene expression are the positive expression of CK 5/6 and
EGFR and the negative expression of HER2 and ER; these
criteria were associated with a sensitivity of 76% and a
specificity 100%.12 In this study, we analyzed these markers;
however, it should be noted that other studies have
considered the expression patterns of CK5, CK14, CK 17,
p-cadherin, p63, c-kit, and vimentin to characterize a basal-
like phenotype.19-22 Differences in the molecular profile of
basal-like carcinomas have also been associated with protein
expression patterns of physiological stem/progenitor cells
during breast development.23 In this histogenetic model,
adult CK5-positive stem cells are hypothesized to differ-
entiate into neoplastic stem cells as a result of EGFR
amplification, a mutation of p53, or BRCA inactivation, and
this differentiation leads to the generation of basal-like
carcinomas. In general, these types of tumors express high
levels of p-cadherin, EGFR, and CK5 and an absence or low
levels of luminal markers, such as CK 8/18.23 Given the
number of markers involved, the possibility that different
expression profiles could define distinct subsets of basal-like
carcinomas should be considered. For example, Rakha et al.
compared tumors with a basal phenotype that were
characterized by the expression of basal cytokeratins
(CK5/6 or CK14) with cells with a myoepithelial phenotype
(p63 or smooth muscle actin).24 The basal phenotype was
associated with a worse outcome, which suggested that
although basal and myoepithelial phenotypes share many
features, including a similar genetic profile, they possible
are distinct tumors.24
Very few studies exist that have examined molecular
differences in breast tumors according to age.1-3,9,16,25 In the
present study, a higher prevalence of TN carcinoma was
observed in younger patients (34.3% for younger patients vs.
16.3% for older patients), and a basal-like phenotype
associated with positive expression of CK5/6 and/or
EGFR was present in 74.3% vs. 68.4%, respectively. More
importantly, the molecular profiles of the TN carcinomas
from younger patients were different from the profiles of
the tumors from older patients. Triple negative carcinomas
in the younger age group were more frequently EGFR
positive (71.6% vs. 47.3%, respectively) and less frequently
Figure 1 - A high-grade invasive ductal carcinoma (A) with
intense, diffuse CK5/6 immunoexpression (B).
Figure 2 - A high-grade invasive ductal carcinoma with numerous
mitotic figures (A) and EGFR immunoexpression (B).
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CK5/6 positive (9.4% vs. 42.1%, respectively). The role of
EGFR expression in breast cancer has been investigated by
many authors.11,14,26,27 Viale et al. reported a worse prog-
nosis for patients with TN carcinomas that had EGFR-
immunoreactivity present in more than 50% of neoplastic
cells, which suggested a possible prognostic role for
quantification.14 Similarly, Rimawi et al. used radioligand-
binding assays to quantify EGFR expression in frozen
sections of breast tissue carcinomas and found that higher
levels of EGFR were associated with younger and black
women, a more aggressive outcome, and lower levels of
hormone receptors.27 The relationship between EGFR and
BRCA1 has been investigated by different groups, and
BRCA1-germline mutations have been associated with a
basal-like phenotype and younger age.8-11 In a study by
Collins et al. that analyzed BRCA1 in 144 TN carcinomas,
independent of the patient’s age,26 they found a higher
prevalence of basal CK and EGFR among TN breast cancers;
however, the frequency of expression of these markers was
similar in women with and without BRCA1 mutations.26 In
contrast, Arnes et al. found that EGFR was a predictor of
BRCA1 status, followed by patient age and ER status.11 In
the same study, a worse prognosis was associated with a
mutation of BRCA1 and positive expression of EGFR.11
As a receptor tyrosine kinase that plays essential roles in
both normal physiological conditions and cancerous condi-
tions, EGFR can affect many important characteristics of a
cancer’s phenotype, including evasion of apoptosis, prolif-
eration, invasion, and metastasis. In a previous study, the
frequency of EGFR-positive tumors among young patients
was found to be higher than among older women (5.9% vs.
3.3%, respectively), although the difference was not statis-
tically significant.16 Based on the results of that study and
the data presented in this report, EGFR expression appears
to play an important role in the early onset of breast cancer,
and we hypothesize that this role is related to intrinsic
genetic differences that result in an adverse outcome that is
associated with the aggressive breast carcinomas. Further-
more, we propose that EGFR immunostaining and/or
amplification should be further investigated as predictor
of a patient’s response to targeted therapy.
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